Micro Marvel – Y-Mabs Therapeutics

MicroMarvel is a series of articles highlighting undercovered stocks with less than a billion dollars in Market Capitalization. These articles are not intended to be buy recommendations. They highlight stocks that may have limited trading volume and may be highly volatile, so if you do decide to add them to your portfolio I highly recommend you use stop losses and limit orders.turned-on MacBook ProPhoto by on
 Today’s MicroMarvel is the biotechnology company Y-mAbs Therapeutics (). I found the stock by using Barchart’s screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum, and having a Trend Seeker buy signal, then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Seeker signaled a buy on 11/29 the stock gained 140.54%.YMAB Price vs Daily Moving Averages (Barchart)
 Barchart Technical Indicators:

  • 100% technical buy signals
  • 151.56+ Weighted Alpha
  • 245.19% gain in the last year
  • Trend Seeker buy signal
  • Above its 20, 50, and 100-day moving averages
  • 12 new highs and up 48.81% in the last month
  • Relative Strength Index 77.70%
  • Technical support level at $13.39
  • Recently traded at $14.36 with a 50-day moving average of $8.83
     
  • Fundamental Factors:

  • Market Cap $572 million
  • Wall Street projected Revenue will grow 26.00% this year and another 18.80% next year
  • Earnings are estimated to increase 68.90% this year but decrease 8.80% next year and continue to decrease at an annual rate of 88.60% for the next 5 years
  • Analysts and Investor Sentiment — I don’t buy stocks just because everyone else is buying, but I do realize that if major firms and investors are dumping a stock it’s hard to make money swimming against the tide:

  • Wall Street issued 2 strong buy, 2 buy, 1 hold, and 1 underperform recommendation on the stock
  • Their price targets are between $5 and $22 – a very wide range with a consensus of $13.67 for a loss of 5%
  • The individual investors following the stock on Motley Fool  voted 2 to 1 for the stock to beat the market
  • Value Line give the stock its average rating of 3
  • CFRAs Market Scope rates the stock a buy
  • 1,750 investors monitor the stock on Seeking Alpha
  • More By This Author:

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    This site uses Akismet to reduce spam. Learn how your comment data is processed.